TFF Group (TFFP)
Dec 13, 2024 - TFFP was delisted (reason: winding down operations)
0.0650
-0.0977 (-60.05%)
Inactive · Last trade price on Dec 12, 2024
TFF Pharmaceuticals Balance Sheet
Financials in millions EUR. Fiscal year is May - April.
Millions EUR. Fiscal year is May - Apr.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '25 Oct 31, 2025 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 |
Cash & Equivalents | 96.71 | 79.67 | 92.94 | 102.34 | 97.58 | 94.64 |
Cash & Short-Term Investments | 96.71 | 79.67 | 92.94 | 102.34 | 97.58 | 94.64 |
Cash Growth | 21.39% | -14.29% | -9.18% | 4.88% | 3.10% | 15.39% |
Accounts Receivable | 84.66 | 81.1 | 99.66 | 98.57 | 78.48 | 47.86 |
Other Receivables | 15.08 | 26.83 | 17.01 | 16.49 | 7.28 | 12.35 |
Total Trade Receivables | 99.74 | 107.93 | 116.66 | 115.06 | 85.76 | 60.21 |
Inventory | 428.97 | 451.59 | 417.13 | 345.94 | 277.15 | 256.6 |
Total Current Assets | 625.42 | 639.19 | 626.74 | 563.34 | 460.49 | 411.46 |
Net Property, Plant & Equipment | 206.24 | 209.19 | 202.02 | 151.86 | 140.16 | 125.2 |
Other Intangible Assets | 5.12 | 5.25 | 5.12 | 4.99 | 4.6 | 4.47 |
Goodwill | 113.35 | 114.26 | 108.18 | 99.22 | 101.4 | 85.98 |
Long-Term Investments | 19.9 | 24.51 | 18.44 | 17.37 | 15.74 | 16.55 |
Other Long-Term Assets | 11.49 | 2.75 | 8.5 | 6.78 | 12.61 | 16.01 |
Total Assets | 981.52 | 995.14 | 968.99 | 843.55 | 735 | 659.67 |
Accounts Payable | 20.54 | 28.64 | 40.6 | 46.32 | 25.94 | 18.71 |
Current Portion of Long-Term Debt | - | 246.11 | 245.52 | 240.47 | 155.33 | 153.48 |
Other Current Liabilities | 25.34 | 35.78 | 43.61 | 36.63 | 36.73 | 18.81 |
Total Current Liabilities | 295.39 | 310.53 | 329.74 | 323.42 | 218 | 191.01 |
Long-Term Debt | 397.73 | 147.57 | 114.01 | 46.03 | 79.11 | 79.17 |
Other Long-Term Liabilities | 20.7 | 18.67 | 14.12 | 11.86 | 11.78 | 15.75 |
Total Long-Term Liabilities | 168.93 | 166.24 | 128.13 | 57.89 | 90.88 | 94.92 |
Total Liabilities | 464.31 | 476.77 | 457.86 | 381.31 | 308.88 | 285.93 |
Common Stock | 8.67 | 8.67 | 8.67 | 8.67 | 8.67 | 8.67 |
Additional Paid-in Capital | 488.02 | 468.68 | 425.19 | 386.33 | 358.88 | 346.72 |
Accumulated Other Comprehensive Income | -26.22 | -20.49 | -0.61 | -5.36 | 4.14 | -7.09 |
Retained Earnings | 15.3 | 30.71 | 56.45 | 52.82 | 35.86 | 20.04 |
Total Common Shareholders' Equity | 485.77 | 487.57 | 489.7 | 442.45 | 407.54 | 368.34 |
Minority Interest | 31.44 | 30.8 | 21.42 | 19.78 | 18.58 | 5.4 |
Shareholders' Equity | 517.21 | 518.37 | 511.12 | 462.24 | 426.12 | 373.74 |
Total Liabilities & Equity | 981.52 | 995.14 | 968.99 | 843.55 | 735 | 659.67 |
Total Debt | 397.73 | 393.69 | 359.53 | 286.5 | 234.44 | 232.65 |
Net Cash (Debt) | -301.03 | -314.02 | -266.59 | -184.16 | -136.86 | -138.01 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -13.89 | -14.49 | -12.30 | -8.50 | -6.30 | -6.33 |
Book Value | 485.77 | 487.57 | 489.7 | 442.45 | 407.54 | 368.34 |
Book Value Per Share | 22.42 | 22.50 | 22.59 | 20.41 | 18.75 | 16.91 |
Tangible Book Value | 367.3 | 368.07 | 376.4 | 338.25 | 301.55 | 277.89 |
Tangible Book Value Per Share | 16.95 | 16.99 | 17.37 | 15.61 | 13.88 | 12.76 |